%0 Journal Article %A Oliver Pearson %A Nora Uglik-Marucha %A Kamilla W. Miskowiak %A Scott A. Cairney %A Ivana Rosenzweig %A Allan H. Young %A Paul R.A. Stokes %T The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review %D 2021 %R 10.1101/2021.08.12.21261470 %J medRxiv %P 2021.08.12.21261470 %X Background Cognitive impairment experienced by people with bipolar disorders (BD) or major depressive disorder (MDD) is associated with impaired psychosocial function and poorer quality of life. Sleep disturbance is another core symptom of mood disorders which may be associated with, and perhaps worsen, cognitive impairments. The aim of this systematic review was to critically assess the relationship between sleep disturbance and cognitive impairment in mood disorders.Methods In this systematic review, relevant studies which examined sleep disturbance and cognitive function in people with mood disorders were identified using electronic database searches of PsychINFO, MEDLINE, Embase and Web of Science.Findings Fourteen studies were included; eight investigated people with BD, five investigated people with MDD, and one included both people with MDD and people with BD. One study was an intervention for sleep disturbance and the remaining thirteen studies used either a longitudinal or cross-sectional observational design. Ten studies reported a significant association between subjectively measured sleep disturbance and cognitive impairment in people with MDD or BD after adjusting for demographic and clinical covariates, whereas no such association was found in healthy participants. Two studies reported a significant association between objectively measured sleep abnormalities and cognitive impairment in mood disorders. One study of cognitive behavioural therapy for insomnia modified for BD (CBTI-BD) found an association between improvements in sleep and cognitive performance in BD.Interpretation There is preliminary evidence to suggest a significant association between sleep disturbance and cognitive impairment in mood disorders. These findings suggest that identifying and treating sleep disturbance may be important when addressing cognitive impairment in MDD and BD.Funding none.Competing Interest StatementOP, NUM, SAC and IR declare no competing interests. KWM has received consultancy fees from Lundbeck and Janssen-Cilag in the past three years. Dr. Stokes reports non-financial support from Janssen Research and Development LLC, personal fees and non-financial support from Frontiers in Psychiatry, personal fees from Allergan, a grant from H Lundbeck, grants and non-financial support from Corcept Therapeutics, outside the submitted work. Professor Allan H. Young declares: Employed by Kings College London; Honorary Consultant SLaM (NHS UK) Deputy Editor, BJPsych Open Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS Consultant to Johnson & Johnson Consultant to Livanova Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression. Principal Investigator on The Effects of Psilocybin on Cognitive Function in Healthy Participants Principal Investigator on The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD) UK Chief Investigator for Novartis MDD study MIJ821A12201 Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) No shareholdings in pharmaceutical companiesFunding StatementFunding: none.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No ethical approval required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data was used. %U https://www.medrxiv.org/content/medrxiv/early/2021/08/13/2021.08.12.21261470.full.pdf